Publication | Closed Access

Multicentric neoadjuvant phase II study of panitumumab combined with an anthracycline/taxane-based chemotherapy in operable triple-negative breast cancer: identification of biologically defined signatures predicting treatment impact

Breast OncologyMedicineTreatment ImpactImmunologyPathologyImmune Checkpoint InhibitorBreast CancerAnthracycline/taxane-based ChemotherapyCancer TreatmentOncologyTumor Biology